The metformin in tuberous sclerosis (MiTS) study: A randomised double-blind placebo-controlled trial

BACKGROUND: Tuberous Sclerosis Complex (TSC) is a genetic disorder characterised by the development of benign tumours secondary to loss of inhibitory regulation of the mTOR (mechanistic Target of Rapamycin) intracellular growth pathway. Metformin inhibits the mTOR pathway. We investigated whether me...

Cijeli opis

Spremljeno u:
Bibliografski detalji
Izdano u:EClinicalMedicine
Glavni autori: Amin, Sam, Mallick, Andrew A, Edwards, Hannah, Cortina-Borja, Mario, Laugharne, Matthew, Likeman, Marcus, O'Callaghan, Finbar J.K.
Format: Artigo
Jezik:Inglês
Izdano: Elsevier 2021
Teme:
Research Paper
Online pristup:https://ncbi.nlm.nih.gov/pmc/articles/PMC7910694/
https://ncbi.nlm.nih.gov/pubmed/33681737
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.eclinm.2020.100715
Oznake: Dodaj oznaku
Bez oznaka, Budi prvi tko označuje ovaj zapis!

Similar Items